Hawaii Patent of the Month – November 2021
Hawaii Biotech Inc. is a biotechnology company targeting infectious diseases. Their R&D efforts work towards vaccines for established and emerging infectious diseases. One vein of focus is targeted towards the eradication of West Nile Virus (WNV). They have recently patented a vaccine designed to protect humans from disease caused by this virus.
WNV is a mosquito-borne member of the family Flaviviridae that has emerged in recent years to become a serious public health threat. Hawaii Biotech’s vaccine combines a recombinant subunit protein derived from the WNV envelope protein and a TLR-4 agonist. TLR-4 has previously been evaluated pre-clinically as components of vaccine adjuvants . This adjuvant is parto fa group of TLRs – or toll-like receptors – which engage the innate immune system to stimulate a more robust and durable adaptive immune response. When joined with a purified WNV envelope polypeptide, the vaccine can target and mount an effective immune response against WNV – protecting the vaccinated individual. The vaccine has proven to be effective in mouse models up to 300 days following a single immunization.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
